Onychomycosis, commonly known as toenail fungus, is a prevalent fungal infection that affects the nails, particularly those on the toes. Caused primarily by dermatophytes—fungi that thrive on keratin, the protein in nails—this condition leads to unsightly and sometimes uncomfortable changes in the nail’s appearance and structure. Symptoms include thickening of the nail, discoloration ranging from yellow to brown or white, brittleness that causes cracking or breaking, and in some cases, separation from the nail bed. While not typically painful, it can become so if left untreated, especially in individuals with compromised immune systems or poor circulation. Onychomycosis is more common in older adults, affecting up to 20% of those over 60, and is exacerbated by factors like diabetes, peripheral vascular disease, or frequent exposure to moist environments such as public showers or pools. The infection is contagious, spreading through direct contact or contaminated surfaces, making prevention crucial. Despite its commonality, treating onychomycosis can be challenging due to the nail’s slow growth rate—often taking 12 to 18 months for a full toenail to regrow—and the fungus’s resilience.
Diagnosis is a critical first step before initiating treatment. Healthcare professionals, such as dermatologists or podiatrists, typically begin with a visual examination of the affected nails. To confirm the fungal cause and rule out conditions like psoriasis or trauma, laboratory tests may be employed. These include a potassium hydroxide (KOH) preparation, where nail clippings are examined under a microscope for fungal elements, or a fungal culture to identify the specific pathogen. In some cases, a nail biopsy or PCR testing provides more definitive results. Accurate diagnosis ensures targeted therapy, as different fungi—dermatophytes account for 90% of cases, but yeasts like Candida or molds can also be culprits—may respond differently to treatments. Once confirmed, treatment selection depends on factors like the infection’s severity (mild, moderate, or severe based on nail involvement), the number of affected nails, patient age, comorbidities, and preferences regarding side effects and cost.
Oral antifungal medications represent the cornerstone of treatment for moderate to severe onychomycosis, offering the highest cure rates due to their systemic action. Terbinafine (Lamisil) is widely regarded as the most effective, with mycological cure rates (elimination of fungus) ranging from 70% to 81% and complete cure rates (normal-looking nail plus mycological cure) around 38% to 76% in clinical trials. Administered daily for 12 weeks for toenails, it inhibits fungal ergosterol synthesis, leading to cell death. Itraconazole (Sporanox) is another option, with cure rates of 46% to 69%, often given in a pulsed regimen (one week on, three weeks off) for three months. Fluconazole (Diflucan) is less commonly used but effective for certain cases, particularly Candida infections. These drugs promote the growth of a new, healthy nail that gradually replaces the infected one, with full results visible after several months of nail regrowth.
The advantages of oral therapies include high efficacy against dermatophytes and non-dermatophyte molds, shorter treatment durations compared to topicals, and excellent patient adherence—often exceeding 90% due to the convenience of pill-taking. However, they are not without drawbacks. Side effects can include gastrointestinal disturbances (nausea, diarrhea in about 5% of users), cutaneous reactions like rashes (3%), and rare but serious hepatotoxicity (0.04% incidence). Drug interactions are a concern, especially with itraconazole, which affects cytochrome P450 enzymes, potentially interacting with statins or anticoagulants. Liver function tests are recommended before and during treatment, particularly for patients with pre-existing liver conditions or those over 65, where success rates may dip. Costs are relatively low, typically under $100 per month for generics, making them accessible. Emerging oral agents like fosravuconazole and VT-1161 show promise in trials, with cure rates up to 82%, potentially offering fewer side effects.
For milder cases or patients unable to tolerate oral medications, topical treatments provide a safer alternative with minimal systemic absorption. Options include ciclopirox 8% nail lacquer (Penlac), applied daily for up to 48 weeks, with mycological cure rates of 34% and complete cures of 5-8%. Newer agents like efinaconazole (Jublia) and tavaborole (Kerydin) offer better penetration through the nail plate, achieving mycological cures of 54% and 46%, respectively, and complete cures of 17% and 15%. These are applied once daily after soaking the nails, often combined with nail debridement (filing or trimming) to enhance efficacy. Pros include low side effects—mostly local irritation like redness or burning—and suitability for pregnant women or those with liver issues. However, adherence is poor due to the lengthy regimen, and costs range from $100 to $500 monthly. Topicals are less effective than orals for severe infections but excel in early-stage or limited nail involvement.
Device-based therapies, such as laser and light treatments, have gained popularity as non-invasive options for patients seeking alternatives to pharmaceuticals. Laser therapy, using systems like 1064 nm Nd:YAG or diode lasers, heats the nail bed to destroy fungi, with strong clinical evidence but variable complete resolution rates not surpassing orals or topicals. Sessions are quick, with mild side effects like transient pain or erythema, and high adherence. Photodynamic therapy (PDT) involves applying a photosensitizer (e.g., 5-aminolevulinic acid) followed by light activation, yielding mycological cures of 29-61%. Low-level laser therapy (LLLT), such as the Lunula device, boasts 70% clinical and 95% mycological cures by generating peroxynitrite to induce fungal apoptosis. These methods are expensive ($100-$1500 per session) and often not covered by insurance, but they appeal to those with comorbidities avoiding systemic drugs. Plasma therapy, an emerging non-thermal approach, shows 54% clinical improvement with no pain.
Procedural interventions serve as adjuncts or last resorts. Nail avulsion (temporary removal) or matrixectomy (permanent) allows direct antifungal application, achieving up to 100% cures when combined with medications, though risks include infection, bleeding, and cosmetic issues. Debridement alone is ineffective but boosts other treatments to 76-77% efficacy. Over-the-counter and home remedies, like tea tree oil (18% cure rate) or Vicks VapoRub (38-83% clearance), offer affordable options with minimal sides but weak evidence, suitable for mild cases or as complements.
Combination therapies often yield superior results, reducing recurrence rates. For instance, oral terbinafine paired with topical amorolfine or laser enhances outcomes in recalcitrant cases, though adherence may suffer from regimen complexity. Patient selection is key: orals for severe infections in healthy individuals, topicals or devices for those with contraindications.
Prevention is integral to long-term management. Keeping feet dry, wearing breathable shoes, avoiding barefoot walks in public areas, and proper nail care—trimming straight across after softening—minimize risk. For diabetics, regular foot checks are essential.
Treating onychomycosis requires patience and tailored approaches. Oral antifungals like terbinafine remain the gold standard for efficacy, while topicals and devices provide safer alternatives. With recurrence rates up to 50%, ongoing prevention and follow-up are vital. Advances in therapies, such as novel orals and non-invasive devices, promise better outcomes as of 2025, emphasizing the importance of consulting specialists for optimal results.